Agomelatine prodrug (Seaport Therapeutics)

阿戈美拉汀前药（Seaport Therapeutics）

Report date: 2026/04/03 20:03:44

Base Information

Drug NameAgomelatine prodrug (Seaport Therapeutics)
Drug Alias NameGlyph AgomelatineGlyphAgoLYT-320SPT-320
ClassificationSmall molecules
Mechanisms of ActionMelatonin receptor 1A agonistsSerotonin 2c (5-HT2c) receptor antagonistsMelatonin receptor 1B agonists
TargetsMelatonin receptor 1ASerotonin 2c (5-HT2c) receptorMelatonin receptor 1B
Therapy Area/IndicationsDepressive Disorder, MajorAnxiety Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSeaport Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesSeaport Therapeutics
Inactive CompaniesN/A
Active IndicationsDepressive Disorder, MajorAnxiety Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A